Lung cancer remains one of the leading causes of cancer-related deaths worldwide, and what is alarming is that lung cancer in women has been steadily rising over the past decade. According to global cancer statistics, lung cancer accounts for more than 2.4 million new cases annually, and a significant portion of this burden is increasingly seen among women—including those who have never smoked. This shift highlights an urgent need to recognize early signs, understand risk factors, and seek expert care from specialists like Dr. Mathangi, a leading Senior Consultant & In-charge of Radiation Oncology at Gleneagles Cancer Institute, Bangalore.
If you are a woman seeking clarity about symptoms, risk factors, or treatment options, this comprehensive guide provides everything you need to know—structured in a way that directly answers common questions and gives you confidence to take the next step toward expert care.
Lung cancer in women refers to cancer that begins in the lung tissues and disproportionately affects women due to hormonal factors, environmental exposure, genetic influences, and rising cases of non-smoker lung cancer. Women are now more likely to develop adenocarcinoma, a subtype of lung cancer, even without traditional risk factors like smoking.
Experts believe that women may have increased susceptibility to certain carcinogens, higher likelihood of developing EGFR mutation-driven tumors, and unique hormonal interactions that alter cancer behavior. This makes timely diagnosis essential, especially if symptoms appear subtle.
Young women lung cancer is increasingly reported worldwide, particularly affecting women under 50 who have never smoked. Studies show this rise is linked to genetic mutation patterns, passive smoke exposure, air pollution, and hormonal influences. Adenocarcinoma is the most common subtype in this demographic.
Dr Mathangi emphasizes that young women often ignore early symptoms, attributing them to allergies or fatigue, leading to delayed diagnosis. Early imaging and genetic testing play a vital role in identifying lung cancer early in young women.
Adenocarcinoma in women is the most common form of lung cancer affecting females, especially non-smokers. It arises in the peripheral lung tissue and is strongly associated with EGFR mutation and other driver mutations. Women with adenocarcinoma often present with persistent cough, breathlessness, or recurrent lung infections.
This subtype responds well to targeted therapies when detected early, making molecular testing essential. Under the expertise of specialists like Dr Mathangi, patients receive a personalized treatment plan that increases success rates and preserves long-term lung function.
Non-smoker lung cancer is a major concern among women, particularly in India. Research shows that up to 50% of female lung cancer patients have never smoked. Key causes include:
Women’s lung biology makes them more vulnerable to environmental toxins, making preventive care and early screening essential.
Early symptoms may be subtle, but recognizing them early can significantly improve survival. Common symptoms include:
Women often experience delayed diagnosis because these signs mimic asthma or seasonal allergies. Dr Mathangi strongly advises medical evaluation if symptoms persist beyond two weeks.
Diagnosis requires a combination of imaging, biopsy, and advanced molecular profiling. Dr Mathangi follows a comprehensive evaluation pathway with:
This precision-driven approach ensures that each patient receives the most effective, personalized treatment plan.
Lung cancer treatment varies depending on stage, tumor type, genetic mutations, and overall health. At Gleneagles Cancer Institute, Bangalore, Dr Mathangi offers an integrated, multidisciplinary treatment approach that includes:
Used for early-stage, operable tumors. Minimally invasive techniques ensure faster recovery.
Highly effective for tumors with mutations such as EGFR mutation. These therapies block cancer growth pathways and often lead to dramatic tumor shrinkage.
Helps the immune system recognize and attack cancer cells. Often used in advanced stages.
Radiation therapy for lung cancer plays a vital role in both early-stage and advanced disease. Under Dr Mathangi’s guidance, cutting-edge techniques such as Stereotactic Body Radiation Therapy (SBRT), Gated RapidArc, and DIBH (breath-hold) radiotherapy ensure:
Her expertise in installing Asia Pacific’s first TrueBeam STx machine showcases her excellence in advanced radiation oncology.
With over 20 years of experience and more than 12,000 patients treated successfully, Dr. Mathangi is a recognized leader in radiation oncology. She specializes in lung cancers, head and neck cancers, brain tumors, breast cancers, uterine cancers, cervical cancer, and more.
Her international training in SRS/SBRT (Germany), IGRT/RapidArc (Denmark), and IORT allows her to deliver world-class cancer care with exceptional precision. For women diagnosed with lung cancer, her evidence-based approach ensures unmatched treatment outcomes.
You can easily book an appointment by submitting your contact information on the official website. Visit the link below:
https://drmathangi.com/contact/
Her dedicated team will reach out to schedule your consultation promptly.
Dr Mathangi is a Senior Consultant & In-charge of Radiation Oncology at Gleneagles Cancer Institute, Bangalore. With MBBS, DMRT, and DNB qualifications, she is renowned for her skill in Stereotactic Radiotherapy, RapidArc, Gated Radiotherapy, and Interstitial Brachytherapy. Her leadership and academic contributions make her a cornerstone in India’s oncology landscape.
While lung cancer can affect anyone, lung cancer in women can differ from men in terms of age at diagnosis, type of tumor, genetic changes in the cancer cells, and risk factors. Women are more likely to have certain non-smoking-related drivers of cancer growth, and may present with persistent cough, breathlessness, chest discomfort, fatigue, or unexplained weight loss rather than classic heavy-smoker symptoms. Because of these differences, Dr. Mathangi focuses on tailored evaluation for each woman, including detailed imaging, lung function assessment, and molecular profiling, so that diagnosis and treatment are aligned with a woman’s overall health, hormones, lifestyle, and future quality of life.
Yes. It is a common myth that lung cancer affects only older men with a long history of smoking. In reality, young women lung cancer cases are increasingly recognised worldwide, and many of these patients have minimal or no smoking exposure. This type of non-smoker lung cancer is often driven by specific genetic alterations in the cancer cells, family history, exposure to pollution, second-hand smoke, or indoor toxins. When a younger woman has a persistent cough, breathing difficulty, or unexplained chest pain that does not settle, Dr. Mathangi recommends timely evaluation with chest imaging and, if needed, a biopsy and molecular tests. Early diagnosis allows for highly targeted treatment and better long-term outcomes, particularly for younger women who may be juggling careers, families, and caregiving roles.
Adenocarcinoma is a type of lung cancer that starts from the gland-like cells lining the airways. It tends to occur in the outer parts of the lung and is now the most common type of lung cancer seen worldwide, especially among women and non-smokers. In adenocarcinoma in women, the cancer cells often carry subtle genetic changes that drive their growth, which can sometimes be controlled with targeted medicines rather than traditional chemotherapy alone. When Dr. Mathangi evaluates a woman with suspected adenocarcinoma, she emphasises accurate biopsy, detailed staging scans, and advanced molecular tests, because understanding the exact subtype and driver mutations helps her recommend the most effective and least disruptive treatment plan.
An EGFR mutation is a change in the epidermal growth factor receptor gene within the lung cancer cells. This mutation is seen more frequently in women, especially in those who have never smoked or have smoked very little. When an EGFR mutation is present, the tumour can often be treated with oral targeted therapy drugs that specifically block this abnormal signal, helping to shrink or control the cancer with fewer side effects than some conventional treatments. As part of her workup, Dr. Mathangi routinely recommends comprehensive molecular testing on biopsy samples where appropriate, including EGFR and other relevant genes, so that women are not denied the benefits of precision medicine simply because their disease appears “typical” on a scan.
Diagnosing lung cancer accurately starts with a detailed consultation and examination. Based on symptoms and risk factors, Dr. Mathangi arranges tests such as chest X-ray, CT scan, PET-CT, and sometimes bronchoscopy or CT-guided biopsy to obtain tissue. The tissue is then analysed under the microscope by a pathologist, and additional immunohistochemistry and molecular tests may be ordered. Staging involves determining the size of the tumor, whether nearby lymph nodes are involved, and if the cancer has spread to other organs. This information allows Dr. Mathangi to classify the disease as early, locally advanced, or metastatic and to design a treatment plan that is appropriate for a woman’s stage, general health, preferences, and life goals.
Treatment is highly individualised. Depending on the stage and biology of the tumour, options may include surgery, chemotherapy, targeted therapy, immunotherapy, and radiation therapy for lung cancer, or a thoughtful combination of these. For early-stage disease, surgery with or without adjuvant treatment may be recommended. For more advanced stages, carefully planned radiotherapy with modern techniques, systemic therapy based on molecular profiling, and symptom-directed supportive care can help control the disease and maintain quality of life. Throughout this journey, Dr. Mathangi and her multidisciplinary team focus on explaining choices clearly, managing side effects, preserving lung function, and offering emotional and practical support to the patient and her family.
Personalised care goes beyond choosing a drug or radiation plan. During consultations, Dr. Mathangi considers a woman’s age, fertility wishes, family responsibilities, work demands, existing medical conditions, and emotional wellbeing. She aims to schedule treatments and follow-up visits in a way that fits each patient’s life, while still maintaining oncological safety. Follow-up typically includes regular physical examinations, imaging at recommended intervals, assessment of treatment response, and proactive management of issues like fatigue, breathlessness, nutrition, and mental health. Lifestyle guidance on exercise, diet, and avoiding lung irritants is integrated into every stage of care, helping women feel supported not just as patients, but as whole individuals.
You should consider a consultation if you have a persistent cough for more than a few weeks, blood in sputum, unexplained chest pain, breathlessness on routine activities, voice changes, recurring chest infections, or unexplained weight loss. Women with a strong family history of lung or related cancers, significant exposure to passive smoke, occupational fumes, or high levels of air pollution may benefit from an early assessment even if symptoms are mild. Meeting Dr. Mathangi early does not automatically mean you have cancer; in many cases, she can reassure you or treat benign conditions. But if something serious is detected, this early step can make a meaningful difference in the success of treatment and long-term outcome.
Your information is kept strictly confidential.
